Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
Back Bay Life Science Report
by Jonathan P. Gertler and Peter Bak
1w ago
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian Thienel Length: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our opinions and perspectives on these topics. Our team has written these whitepapers to address industry interest: The Radiopharmaceutical Renaissance: Radiating Hope in Medicine Vision of Commercial Success: Investment and Partnering Landscape for Psy ..read more
Visit website
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
Back Bay Life Science Report
by Jonathan P. Gertler and Peter Bak
1M ago
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology.     In this episode:   CRISPR and Vertex’s approval of Exa-cel, the first CRISPR-based genetic medicine approved by the FDA in the US  The major depressive disorder vs. postpartum depression for Biogen/Sage  GenMab and Roche approv ..read more
Visit website
Monthly Roundup of News from Healthcare Development
Back Bay Life Science Report
by Jonathan P. Gertler
3M ago
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area.   In this next installment of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors talk about kidney disease and the various aspects of the renal disease landscape.   Topics in this podcast include: The links between cardio and metabolic di ..read more
Visit website
The Current and Future Landscape of Healthcare IPO Markets
Back Bay Life Science Report
by Jonathan P. Gertler
4M ago
with the DNB//Back Bay Partnership for Healthcare In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public this year, including Schott Pharma, Germany’s largest IPO earlier this year. In the first podcast episode with the DNB//Back Bay Partnership for Healthcare, Jonathan Gertler, Back Bay CEO and Managing Partner is joined by Jim Cirenza, Head of Fixed ..read more
Visit website
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
Back Bay Life Science Report
by Jonathan P. Gertler
4M ago
A conversation on the rising trends in the cardiology space Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology. During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications. Episode topics include:  Why pharma’s intere ..read more
Visit website
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
Back Bay Life Science Report
by Peter Bak, PhD
6M ago
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including: Background information on the class of therapeutics known as ADCs, which have been on the market since 2000 The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment Deal structures and ..read more
Visit website
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
Back Bay Life Science Report
by Jonathan P. Gertler
11M ago
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of care while reducing healthcare costs.     In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler speaks with Mikaela Odlander, Director of Digital Therapeutics at Orexo, and Edward Kliphuis, Investment Di ..read more
Visit website
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
Back Bay Life Science Report
by Jonathan P. Gertler
1y ago
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting.   In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce.    In this episode of Back Bay’s industry podcas ..read more
Visit website
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
Back Bay Life Science Report
by Jonathan P. Gertler
1y ago
In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape,  these stories captivated us and continue to herald progress in health and human care.  Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon ..read more
Visit website
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
Back Bay Life Science Report
by Jonathan P. Gertler
1y ago
For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something like this is predicated on an amalgam of strategic decisions.  In this episode Back Bay Life Science Advisors ..read more
Visit website

Follow Back Bay Life Science Report on FeedSpot

Continue with Google
Continue with Apple
OR